The Patent Finder
BF

Biomea Fusion, Inc.

First filing 2019
OverviewNotableFeesChangesFamiliesPatent listSources & methods

12 patents currently held

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Dec 2039. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Dec 2039
Next term end
7
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents all others Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jan 18, 2027
    The maintenance fee for Substituted Pyridines as Irreversible Inhibitors of Menin-Mll Interaction (US 11,702,421) comes due Jan 18, 2027. Unpaid by Jul 19, 2027, it lapses early.
  • 1 fee due Jun 19, 2027
    The maintenance fee for Inhibitors of Menin-Mll Interaction (US 11,845,753) comes due Jun 19, 2027. Unpaid by Dec 20, 2027, it lapses early.
  • 1 fee due Oct 2, 2027
    The maintenance fee for Pyrazine Compounds as Inhibitors of FLT3 (US 11,945,785) comes due Oct 2, 2027. Unpaid by Apr 3, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 11,084,825Substituted Pyridines as Irreversible Inhibitors of Menin-Mll Interaction
In force
 · High confidence
In forceHigh confidence
US 11,174,263Inhibitors of Menin-Mll Interaction
In force
 · High confidence
In forceHigh confidence
US 11,702,421Substituted Pyridines as Irreversible Inhibitors of Menin-Mll Interaction
In force
 · Low confidence
In forceLow confidence
US 11,845,753Inhibitors of Menin-Mll Interaction
In force
 · High confidence
In forceHigh confidence
US 12,116,371Substituted Pyridines as Irreversible Inhibitors of Menin-Mll Interaction
In force
 · Medium confidence
In forceMedium confidence
US 12,275,739Inhibitors of Menin-Mll Interaction
In force
 · High confidence
In forceHigh confidence
US 12,077,544Irreversible Inhibitors of Menin-Mll Interaction
In force
 · Medium confidence
In forceMedium confidence
US 12,018,032CRYSTALLINE FORMS OF N-[4-[4-(4-Morpholinyl)-7H-PYRROLO[2,3-d]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO-2-Propen-1-YL)AMINO]-1-Piperidinyl]METHYL]-2-Pyridinecarboxamide AS AN IRREVERSIBLE INHIBITOR OF MENIN-MLL INTERACTION
In force
 · High confidence
In forceHigh confidence
US 11,945,785Pyrazine Compounds as Inhibitors of FLT3
In force
 · High confidence
In forceHigh confidence
US 12,251,385Covalent Inhibitors of Menin-Mll Interaction for Diabetes Mellitus
In force
 · High confidence
In forceHigh confidence
10 of 12 patents shown.
Pro members see all 12.
Pro members: see all 12 patents
Also on record, not counted in the 12: 13 applications pending · 2 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited